Pawan Karanam, MD

Current Trials

• Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma

  HIC ID2000029793RoleSub InvestigatorPrimary Completion Date04/30/2028

  Recruiting Participants

  Lymphoma

• A Phase II/III Trial of Chemotherapy + Cetuximab vs Chemotherapy + Bevacizumab vs Atezolizumab + Bevacizumab Following Progression on Immune Checkpoint Inhibition in Recurrent/Metastatic Head and Neck Cancers

  HIC ID2000032270RoleSub InvestigatorPrimary Completion Date12/15/2027

  Recruiting Participants

  Head and Neck Cancers

• Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

  HIC ID2000032879RoleSub InvestigatorPrimary Completion Date12/31/2026

  Recruiting Participants

  Lung Cancer

• An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1)

  HIC ID2000025449RoleSub InvestigatorPrimary Completion Date10/30/2023

  Recruiting Participants

  Breast Cancer

• SIMCAP (Surgery in Metastatic Carcinoma of Prostate): Phase 2.5 Multi-Institution Randomized Prospective Clinical Trial Evaluating the Impact of Cytoreductive Radical Prostatectomy Combined With Best Systemic Therapy on Oncologic and Quality of Life Outcomes in Men With Newly Diagnosed Metastatic Prostate Cancer

  HIC ID2000031290RoleSub InvestigatorPrimary Completion Date10/31/2024

  Recruiting ParticipantsGenderMaleAge18+ years

  Prostate Cancer